How to reduce Ki67 variability jointly evaluating histological grade
- Resource Type
- Authors
- Maxim Izquierdo; Ignacio Rodríguez; F. Tresserra; Rafael Fábregas
- Source
- Journal of Clinical Oncology. 33:127-127
- Subject
- Cancer Research
Pathology
medicine.medical_specialty
Receptor Status
biology
business.industry
High variability
Estrogen receptor
Oncology
Ki-67
Progesterone receptor
biology.protein
Medicine
business
- Language
- ISSN
- 1527-7755
0732-183X
127 Background: Proliferative tumor activity measured immunohistochemically by Ki67 has high variability. Clinical use can be improved if it is considered together with the histological grade. Methods: Ki67 value has been studied in 566 breast cancers between 2007 and 2013 at our Institution using MIBI monoclonal antibody. The histological grade and hormonal receptor status were also evaluated. Results: Histological grade was I in 293 (51.7%) tumors, II in 219 (38.7%) and III in 54 (16.8%) tumors. Estrogen receptor was positive in 166 (29.5%) tumors and progesterone receptor was positive in 95 (16.8%) tumors. None of the tumors with Ki 67 value lower than 10% had histological grade III. Only 7% of tumors with histological grade I had a Ki 67 higher than 25%. Conclusions: It has to be considered to repeat or confirm the values of Ki67 higher than 25% with histological grade I, and Ki67 values lower than 10% in tumors with histological grade III.